Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIDRISE Phase 3 study of STN1013800 for acquired blepharoptosis
2024-513356-15-00Phase 3Authorised
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in acquired blepharoptosis comparing STN1013800 with Placebo (2 arms). Primary endpoint: Change from baseline in MRD1 on Day 14. Planned start Dec 2024; status: authorised.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on 2024-513356-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513356-15-00.